Sarepta Therapeutics: What Now After FDA Delay?

With the recent FDA delay, what's the deal with Sarepta Therapeutics.  Seems like a sure thing but then why would the FDA delay their decision and request more data.

A good look at their clinical trail is in the WSJ this week.  Where's the drug FDA?

The Food and Drug Administration is sitting on a therapy for Duchenne muscular dystrophy, and the agency may have days to waste but the boys don’t. Bureaucratic malpractice on a safe and effective treatment is corroding the agency’s scientific credibility and the public’s trust.

FDA in May delayed a decision on eteplirsen by Boston-based Sarepta Therapeutics. There is no treatment for Duchenne, a fatal disease that claims a boy’s ability to walk before organ failure in his 20s. Eteplirsen jumps over genetic code to produce a missing protein known as dystrophin.

Read more at WSJ(FYI, if you google the link title you can get around their purchase options sometimes)

A look at their stock profile:  $SRPT



I have enjoyed CNBC Meg Terrill's Look at Biopharma lately as well with the upcoming elections and terrible year that Biotech has been having.

Check out more videos of Meg here.  http://www.cnbc.com/meg-tirrell/

Biopharma Investor Further Development - Stock Trading

So it's been a minute.  The principles of the Bio Pharmaceuticals of Stock investments still runs true today. I plan on continuing with the Biopharma process and provide more Data Analytical approach with Financial Data in Biotech and Pharmaceuticals.  I went back to school for computer programming and data analysis and now work for a healthcare company in finance. Can't wait to provide better data analysis and web development on this website.  And thankfully have enough time to work on it now.

Singapore Investing

Protein and DNA technologies

4 Best Biopharma Stock Trades 2013

Below are some of the best trades in the Biopharma Stock Sector since January 2013. I have gathered my research from a pretty good stock investment forum, 4-Trader.  It's all free.  I would never ask you to pay for anything on my site.  No catches, no gimmicks.

If you want to search for other Sectors or other Countries, you can check them out here:

4-Trader.com Stock Sector Research

4-Trader.com Healthcare Sector:  Biotech and Pharmaceutical 

These are highly potential  breakout stocks that I have researched and just posting their results and how to learn more about these Top Stocks in the Healthcare Sector.  More Specifically Biotech and Pharmaceutical Stocks that I predict will be doing very well in the next year with the stock market doing well and the Obamacare being implemented in 2014.  There were a lot to choose from so I pick the best ones that I thought had potential for further gains.

Make Money Off Obamacare

As bad as Obamacare is for business, I think it will improve the Healthcare Sector in the upcoming year and these are all good stocks that I would recommend.  But you can perform your own due diligence yourself, this are the ones that stuck out to me.

Top 4 Biopharma Trades

These are the all the best trades since January, most are above 50% in stock share growth.  Most have higher potentials for further earnings.  These are my own personal 4 picks that I thought were the best of the bunch.

Santarus Inc. (SNTS)